Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1989-9-6
|
pubmed:abstractText |
We studied 21 dialysis patients who became hypercalcemic without vitamin D or calcium therapy and compared them to 28 dialysis patients who were not hypercalcemic. In the hypercalcemic group, the mean ionized-calcium level was elevated compared to normal subjects (5.4 +/- 0.4 vs. 4.9 +/- 0.1; p less than 0.001), while the ionized-calcium level in the control dialysis patients was below normal (4.5 +/- 0.4 vs. 4.9 +/- 0.1; p less than 0.001). Bone biopsies were performed in all patients. Two thirds of the hypercalcemic patients had low-turnover osteodystrophy (LTO, predominantly osteomalacia), a fraction significantly higher than in the control dialysis patients (13/21 vs. 8/28, respectively; p less than 0.05). The hypercalcemic patients with LTO had markedly elevated surface bone aluminum (63 +/- 24% of all trabecular surfaces). In contrast, the nonhypercalcemic dialysis patients with LTO and all patients with osteitis fibrosa had minimal surface bone aluminum. Hypercalcemic patients with osteitis fibrosa had a significantly lower mean N-terminal parathyroid hormone (PTH) value than did nonhypercalcemic patients with osteitis fibrosa (149 +/- 81 vs. 278 +/- 135 pg/ml, respectively; p less than 0.005). Both mean values were markedly elevated in comparison with those obtained in normal subjects (16 +/- 5 pg/ml). In contrast, patients with LTO, irrespective of the calcium level, had mean PTH values that were not significantly different from those of normal subjects. A PTH level greater than 100 pg/ml was 95% sensitive and 87% specific for osteitis fibrosa, as demonstrated by histomorphometry in nonhypercalcemic dialysis patients. However, this level was only 62% sensitive and 77% specific for a diagnosis of osteitis fibrosa in hypercalcemic dialysis patients.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-8095
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
190-7
|
pubmed:dateRevised |
2007-2-14
|
pubmed:meshHeading |
pubmed-meshheading:2757078-Adult,
pubmed-meshheading:2757078-Aged,
pubmed-meshheading:2757078-Aluminum,
pubmed-meshheading:2757078-Bone and Bones,
pubmed-meshheading:2757078-Female,
pubmed-meshheading:2757078-Fibrous Dysplasia of Bone,
pubmed-meshheading:2757078-Follow-Up Studies,
pubmed-meshheading:2757078-Humans,
pubmed-meshheading:2757078-Hypercalcemia,
pubmed-meshheading:2757078-Male,
pubmed-meshheading:2757078-Middle Aged,
pubmed-meshheading:2757078-Parathyroid Hormone,
pubmed-meshheading:2757078-Renal Dialysis,
pubmed-meshheading:2757078-Renal Osteodystrophy
|
pubmed:year |
1989
|
pubmed:articleTitle |
Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
|
pubmed:affiliation |
Department of Medicine, University of Pittsburgh, Pa.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.
|